Class Action Lawsuit Filed Against Regeneron Pharmaceuticals Over Alleged Misleading Statements
A class action lawsuit has been filed against Regeneron Pharmaceuticals (NASDAQ: REGN) and certain officers for alleged violations of federal securities laws. The suit claims the company made misleading statements regarding its Phase III Fianlimab-Libtayo study, potentially impacting investor decisions.
Tickers: $REGN
Topics: class action false statements Phase III study Regeneron Pharmaceuticals